Kevin Kunzmann

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

The matters of long-term PCOS management may heavily depend on what stage of life the patient is in—and how the disease itself has presented.

An AAPA 2024 poster from University of Utah shows significant disparities in which patients are missed for depression screening, despite a clinic's universal screening protocol.

From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.

A post hoc analysis from FIDELITY shows finerenone could significantly reduce eGFR slopes among patients at risk of worsening CKD due to a heart failure hospitalization.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

Robert O. Cotes, MD, discusses why the proven agent clozapine may still be underutilized in schizophrenia.

Lovinsky-Desir joins Lungcast on World Asthma Day to discuss community-specific burdens of disease, and emerging strategies to manage it.

Nelson discusses how personality disorder care has been slow to apply evidence into practice—and how it's affecting patients.

Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

McIntyre explains why GLP-1/GIP receptor agonists like semaglutide may alter cognitive and psychiatric care similar to cardiometabolic disease.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.

Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.

A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.

Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Data presented at ACP 2024 shows non-White patients may be particularly subjected to more risk of discrimination in their care when ED boarding extends past 24 hours.

A study presented at ACP 2024 shows benefit with preparing to offer pneumococcal vaccination to incoming patients in an ambulatory setting.

New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.

A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.